X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ASTRAZENECA PHARMA ALKEM LABORATORIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x - 155.7 - View Chart
P/BV x 6.6 24.2 27.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALKEM LABORATORIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ASTRAZENECA PHARMA
Mar-14
ALKEM LABORATORIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,285 123.7%   
Low Rs1,232634 194.3%   
Sales per share (Unadj.) Rs417.5189.6 220.2%  
Earnings per share (Unadj.) Rs56.3-0.2 -27,649.8%  
Cash flow per share (Unadj.) Rs64.73.8 1,683.1%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.968.6 426.8%  
Shares outstanding (eoy) m119.5725.00 478.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 66.8%   
Avg P/E ratio x25.1-4,712.7 -0.5%  
P/CF ratio (eoy) x21.8249.6 8.7%  
Price / Book Value ratio x4.814.0 34.4%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65323,988 703.1%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m9,1711,605 571.6%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m49,9154,740 1,053.1%  
Other income Rs m1,64592 1,786.2%   
Total revenues Rs m51,5614,832 1,067.1%   
Gross profit Rs m8,482-130 -6,534.9%  
Depreciation Rs m1,006101 993.9%   
Interest Rs m6710-   
Profit before tax Rs m8,451-139 -6,084.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,6065 31,552.1%   
Profit after tax Rs m6,731-5 -132,243.6%  
Gross profit margin %17.0-2.7 -620.5%  
Effective tax rate %19.0-3.7 -518.6%   
Net profit margin %13.5-0.1 -12,557.2%  
BALANCE SHEET DATA
Current assets Rs m27,0622,726 992.6%   
Current liabilities Rs m15,3242,435 629.3%   
Net working cap to sales %23.56.1 382.5%  
Current ratio x1.81.1 157.7%  
Inventory Days Days6774 90.2%  
Debtors Days Days4141 101.3%  
Net fixed assets Rs m12,6101,035 1,218.0%   
Share capital Rs m23950 478.2%   
"Free" reserves Rs m34,490942 3,659.8%   
Net worth Rs m35,0271,716 2,041.2%   
Long term debt Rs m1,2120-   
Total assets Rs m54,3874,156 1,308.6%  
Interest coverage x13.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 80.5%   
Return on assets %13.6-0.1 -11,112.3%  
Return on equity %19.2-0.3 -6,478.8%  
Return on capital %24.90-  
Exports to sales %12.95.7 227.1%   
Imports to sales %3.16.5 47.8%   
Exports (fob) Rs m6,461270 2,391.2%   
Imports (cif) Rs m1,540306 502.9%   
Fx inflow Rs m6,563375 1,752.1%   
Fx outflow Rs m3,012470 640.6%   
Net fx Rs m3,552-96 -3,717.0%   
CASH FLOW
From Operations Rs m7,259-8 -89,611.1%  
From Investments Rs m1,864-146 -1,279.5%  
From Financial Activity Rs m-9,273862 -1,075.5%  
Net Cashflow Rs m-150709 -21.2%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 15.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 12,856 531.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Nov 16, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - WYETH LTD COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS